ATE486130T1 - Durch venezuelian-equine-encephalitis-virus (veev) replikons exprimierte ebola virion- proteine - Google Patents

Durch venezuelian-equine-encephalitis-virus (veev) replikons exprimierte ebola virion- proteine

Info

Publication number
ATE486130T1
ATE486130T1 AT99935350T AT99935350T ATE486130T1 AT E486130 T1 ATE486130 T1 AT E486130T1 AT 99935350 T AT99935350 T AT 99935350T AT 99935350 T AT99935350 T AT 99935350T AT E486130 T1 ATE486130 T1 AT E486130T1
Authority
AT
Austria
Prior art keywords
veev
replicons
encephalitis virus
proteins expressed
equine encephalitis
Prior art date
Application number
AT99935350T
Other languages
English (en)
Inventor
Mary Hart
Julie Wilson
Peter Pushko
Jonathan Smith
Original Assignee
U S Medical Res Inst Of Infect
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by U S Medical Res Inst Of Infect filed Critical U S Medical Res Inst Of Infect
Application granted granted Critical
Publication of ATE486130T1 publication Critical patent/ATE486130T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14211—Marburgvirus, e.g. lake Victoria marburgvirus
    • C12N2760/14222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36161—Methods of inactivation or attenuation
    • C12N2770/36162—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT99935350T 1998-06-29 1999-06-22 Durch venezuelian-equine-encephalitis-virus (veev) replikons exprimierte ebola virion- proteine ATE486130T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9140398P 1998-06-29 1998-06-29
PCT/US1999/014311 WO2000000617A2 (en) 1998-06-29 1999-06-22 Ebola virion proteins expressed from venezuelan equine encephalitis (vee) virus replicons

Publications (1)

Publication Number Publication Date
ATE486130T1 true ATE486130T1 (de) 2010-11-15

Family

ID=22227592

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99935350T ATE486130T1 (de) 1998-06-29 1999-06-22 Durch venezuelian-equine-encephalitis-virus (veev) replikons exprimierte ebola virion- proteine

Country Status (8)

Country Link
US (5) US6517842B1 (de)
EP (2) EP1092031A2 (de)
AP (2) AP1944A (de)
AT (1) ATE486130T1 (de)
AU (2) AU767551B2 (de)
CA (2) CA2336554A1 (de)
DE (1) DE69942895D1 (de)
WO (2) WO2000000616A2 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7267823B2 (en) * 1998-06-29 2007-09-11 United States Of America As Represented By The Secretary Of The Army Ebola peptides and immunogenic compositions containing same
EP1092031A2 (de) 1998-06-29 2001-04-18 U.S. Medical Research Institute of Infectious Diseases Marburg-virus impfstoffe
US7736656B2 (en) 1998-06-29 2010-06-15 The United States Of America As Represented By The Secretary Of The Army Immunogenic compositions and vaccines for Ebola
ATE443768T1 (de) * 1998-07-10 2009-10-15 U S Medical Res Inst Of Infect Impfstoff gegen staphylokokken-vergiftung
AU7089600A (en) * 1999-08-30 2001-03-26 U.S. Army Medical Research Institute Of Infectious Diseases Monoclonal antibodies and vaccines against epitopes on the ebola virus glycoprotein
US6783939B2 (en) * 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
WO2002079239A2 (en) * 2001-01-31 2002-10-10 U.S. Army Medical Research Institute Of Infectious Diseases Chimeric filovirus glycoprotein
ES2330202T5 (es) * 2001-09-06 2014-01-20 Alphavax, Inc. Sistemas vectores basados en replicones de alfavirus
US7682618B2 (en) * 2001-11-07 2010-03-23 The United States Of America As Represented By The Secretary Of The Army Generation of virus-like particles and use as panfilovirus vaccine
AU2002352546A1 (en) * 2001-11-07 2003-05-19 U.S. Army Medical Research Institute Of Infections Diseases Department Of The Army Generation of virus-like particles and demonstration of lipid rafts as sites of filovirus entry and budding
US6875433B2 (en) 2002-08-23 2005-04-05 The United States Of America As Represented By The Secretary Of The Army Monoclonal antibodies and complementarity-determining regions binding to Ebola glycoprotein
CA2502863A1 (en) * 2002-10-15 2004-04-29 Phytovation B.V. Expressional enhancers from viruses
CA2509973C (en) * 2002-12-13 2013-02-26 Alphavax, Inc. Multi-antigenic alphavirus replicon particles and methods
MXPA05010007A (es) * 2003-03-20 2006-03-10 Alphavax Inc Replicones de alfavirus y construcciones auxiliares mejorados.
US8372409B2 (en) * 2003-04-09 2013-02-12 University Of Florida Research Foundation, Inc. Dendritic cell binding proteins and uses thereof
US7132398B2 (en) * 2003-05-06 2006-11-07 Dendreon Corporation Method of treatment of hemorrhagic disease using a factor VIIa/tissue factor inhibitor
PT1651666E (pt) * 2003-07-11 2009-08-28 Alphavax Inc Vacinas de citomegalovírus à base de alfavírus
US7524829B2 (en) * 2004-11-01 2009-04-28 Avi Biopharma, Inc. Antisense antiviral compounds and methods for treating a filovirus infection
US7790182B2 (en) 2005-09-21 2010-09-07 The United States Of America As Represented By The Secretary Of The Army Protein vaccines against poxviruses
US7947286B2 (en) * 2005-10-07 2011-05-24 Panthera Biopharma Llc Drosophila cell lines producing recombinant secretable filovirus surface glycoproteins lacking the membrane spanning domain
WO2007127290A2 (en) * 2006-04-24 2007-11-08 Protelix, Inc. Method for producing viral vaccine and therapeutic peptide antigens
WO2008156829A2 (en) * 2007-06-21 2008-12-24 Alphavax, Inc. Promoterless cassettes for expression of alphavirus structural proteins
EP2219671A4 (de) 2007-11-09 2011-02-09 Salk Inst For Biological Studi Verwendung von tam-rezeptorinhibitoren als immu-enhancer und tam-aktivatoren als immunsuppressoren
US8883170B2 (en) 2008-09-03 2014-11-11 Western Illinois University Research Foundation Adjuvant
WO2011071574A2 (en) * 2009-09-02 2011-06-16 United States Deparment Of The Army, As Represented By The Secretary Of The Army Monoclonal antibodies against glycoprotein of ebola sudan boniface virus
ES2711613T3 (es) 2010-04-16 2019-05-06 Us Gov Health & Human Services Vacunas de filovirus basadas en un vector adenovírico de chimpancé
ES2557382T3 (es) 2010-07-06 2016-01-25 Glaxosmithkline Biologicals Sa Liposomas con lípidos que tienen un valor de pKa ventajoso para el suministro de ARN
ES2646669T3 (es) 2010-07-06 2017-12-14 Glaxosmithkline Biologicals Sa Procedimientos de aumento de una respuesta inmunitaria mediante el suministro de ARN
MX342608B (es) 2010-07-06 2016-10-06 Novartis Ag * Particulas de suministro similares a viriones para moleculas de arn de autorreplicacion.
US10487332B2 (en) 2010-07-06 2019-11-26 Glaxosmithkline Biologicals Sa Immunisation of large mammals with low doses of RNA
US8198429B2 (en) 2010-08-09 2012-06-12 Avi Biopharma, Inc. Antisense antiviral compounds and methods for treating a filovirus infection
RS63367B1 (sr) 2010-08-31 2022-07-29 Glaxosmithkline Biologicals Sa Pegilovani lipozomi za isporuku rnk koja kodira imunogen
ES2716243T3 (es) 2010-10-11 2019-06-11 Glaxosmithkline Biologicals Sa Plataformas de suministro de antígenos
EP3854413A1 (de) 2011-07-06 2021-07-28 GlaxoSmithKline Biologicals SA Immunogene kombinationszusammensetzungen und ihre verwendung
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
WO2015187885A1 (en) * 2014-06-03 2015-12-10 The Government Of The United States, As Represented By The Secretary Of The Army Method and composition for determining specific antibody responses to species of filovirus
HUE065565T2 (hu) 2014-09-03 2024-06-28 Bavarian Nordic As Módszerek és készítmények filovírus fertõzés elleni védõ immunitás elõidézésére
BR112017004202A2 (pt) * 2014-09-03 2019-09-03 Bavarian Nordic As composições para intensificar respostas imunes e seus usos
WO2016069853A2 (en) * 2014-10-30 2016-05-06 Cepheid Methods of detecting ebola
WO2017015457A1 (en) * 2015-07-21 2017-01-26 Modernatx, Inc. Ebola vaccine
WO2018011768A1 (en) 2016-07-15 2018-01-18 Janssen Vaccines And Prevention B.V. Methods and compositions for inducing protective immunity against a marburg virus infection
EP3606553A1 (de) 2017-04-06 2020-02-12 Janssen Vaccines & Prevention B.V. Mva-bn- und ad26.zebov- oder ad26.filo-prime-boost-schema
CN108484758B (zh) * 2018-02-11 2020-05-29 浙江大学 抗埃博拉病毒vp40蛋白单克隆抗体a2g7及其应用
RU2739505C1 (ru) * 2020-01-09 2020-12-25 Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) Рекомбинантная плазмидная ДНК pET21-NPVE, содержащая ген нуклеопротеина (NP) вируса Эбола и рекомбинантный белок NP-ВЭ, полученный в результате экспрессии гена NP вируса Эбола с использованием рекомбинантной плазмидной ДНК pET21-NPVE и обладающий иммуногенными и антигенными свойствами
CN111214663B (zh) * 2020-03-06 2022-03-15 中国人民解放军军事科学院军事医学研究院 Tmed2在作为埃博拉病毒病治疗靶点中的应用
CA3176889A1 (en) * 2020-03-26 2021-09-30 Security Matters Ltd. Device and method for detection of viruses by xrf
EP4267593A2 (de) * 2020-12-23 2023-11-01 GlaxoSmithKline Biologicals SA Selbstverstärkende messenger-rna

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792462A (en) 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
US6340463B1 (en) 1996-08-14 2002-01-22 Vanderbilt University Identification of antigenic peptide sequences
US6200959B1 (en) * 1996-12-04 2001-03-13 Powerject Vaccines Inc. Genetic induction of anti-viral immune response and genetic vaccine for filovirus
US5811407A (en) * 1997-02-19 1998-09-22 The University Of North Carolina At Chapel Hill System for the in vivo delivery and expression of heterologous genes in the bone marrow
WO1999032147A1 (en) * 1997-12-23 1999-07-01 The Regents Of The University Of Michigan Immunization for ebola virus infection
US7267823B2 (en) 1998-06-29 2007-09-11 United States Of America As Represented By The Secretary Of The Army Ebola peptides and immunogenic compositions containing same
EP1092031A2 (de) 1998-06-29 2001-04-18 U.S. Medical Research Institute of Infectious Diseases Marburg-virus impfstoffe
AU7089600A (en) 1999-08-30 2001-03-26 U.S. Army Medical Research Institute Of Infectious Diseases Monoclonal antibodies and vaccines against epitopes on the ebola virus glycoprotein
US6875433B2 (en) 2002-08-23 2005-04-05 The United States Of America As Represented By The Secretary Of The Army Monoclonal antibodies and complementarity-determining regions binding to Ebola glycoprotein

Also Published As

Publication number Publication date
AU767147B2 (en) 2003-10-30
US20020164582A1 (en) 2002-11-07
AP2001002060A0 (en) 2001-03-31
US20030152590A1 (en) 2003-08-14
US7455994B2 (en) 2008-11-25
US7090852B2 (en) 2006-08-15
WO2000000616A9 (en) 2001-04-12
WO2000000616A2 (en) 2000-01-06
EP1092031A2 (de) 2001-04-18
EP1119627A2 (de) 2001-08-01
US20040146859A1 (en) 2004-07-29
AP1944A (en) 2009-02-02
WO2000000617A9 (en) 2000-08-03
AU767551B2 (en) 2003-11-13
EP1119627B1 (de) 2010-10-27
WO2000000616A3 (en) 2000-07-06
US6984504B2 (en) 2006-01-10
CA2336554A1 (en) 2000-01-06
AU5084499A (en) 2000-01-17
US6517842B1 (en) 2003-02-11
US20060251681A1 (en) 2006-11-09
WO2000000617A3 (en) 2001-05-31
CA2332494A1 (en) 2000-01-06
WO2000000617A2 (en) 2000-01-06
DE69942895D1 (de) 2010-12-09
AU4709099A (en) 2000-01-17

Similar Documents

Publication Publication Date Title
ATE486130T1 (de) Durch venezuelian-equine-encephalitis-virus (veev) replikons exprimierte ebola virion- proteine
EP0859547A4 (de) Viren inaktivierende umhüllungen
AU3834999A (en) Recombinant venezuelan equine encephalitis virus vaccine
DK1169339T3 (da) Makrocykliske peptider, der inhiberer Hepatitis C-virus NS3-protease
AU7501898A (en) Live attenuated virus vaccines for equine encephalitis viruses
EP1127169A4 (de) Detektion minussträngiger rna-viren
DE69839169D1 (de) Aus infektiöser cDNA gewonnene rekombinate YF Viren-Impfstoffe
DE69735600D1 (de) Konservierung empfindlicher biologischer proben durch verglasung
IS7830A (is) Bóluefni gegn lifrarbólgu C veiru (HCV)
TR199501718A2 (tr) Papaya ringspot virüsü proteaz geni.
DE69702571D1 (de) Lichtempfindliche, wässerig entwickelbare Dickschichtzusammensetzung unter Verwendung von Polyvinylpyrrolidon
DK0716094T3 (da) Fremgangsmåde til oprensning af Hepatitis B-virus-overfladeantigen, som omfatter præS2-peptid
DE69919871D1 (de) Luminiszierende, perforierte, einseitig durchsehbare folie
AU4554899A (en) Novel hepatitis c virus peptides and uses thereof
AU2002257890A1 (en) Method for replicating the hepatitis C virus
ATE240392T1 (de) Spezifische oligonukleotide fuer hepatitis c- virus
AU2003256404A1 (en) Hepatitis c virus assays
EP1210364A4 (de) Impfstoff-antigene von moraxella
BR9506962A (pt) Cultura seletiva de virus
ATE270341T1 (de) Kompakte replikons des epstein-barr-virus.
IT1302442B1 (it) Elemento strutturale autoportante.
AU7618201A (en) Improved virus like particles based on small envelope protein from hepatitis B (HBsAg-S)
FR2749153B1 (fr) Dispositif pour la realisation de ligatures, notamment en orthodontie
GB0215617D0 (en) Use of hepatitis C virus (HCV) p7 protein
FI974623A0 (fi) Loesligt magnesiumdihalogendikomplex, dess framstaellning och anvaendning

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties